SCHEDULE 14A
                    Proxy Statement Pursuant to Section 14(a)
            of the Securities Exchange Act of 1934 (Amendment No. __)


Filed by the Registrant    [  ]

Filed by a Party other than the Registrant    [x]

Check the appropriate box:

[  ]     Preliminary Proxy Statement
[  ]     Confidential, for Use of the Commission Only (as permitted
         by Rule 14a-6(e)(2))
[  ]     Definitive Proxy Statement
[  ]     Definitive Additional Materials
[X]      Soliciting Material Pursuant to ss. 240.14a-12

                             Mylan Laboratories Inc.

                (Name of Registrant as Specified In Its Charter)

                                 Carl C. Icahn,
                   Barberry Corp., Hopper Investments LLC and
                         High River Limited Partnership


    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

[X]      No fee required.

[ ]    Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.

         1)      Title of each class of securities to which transaction applies:



         2)       Aggregate number of securities to which transaction applies:



         3)       Per unit price or other  underlying value of transaction
computed  pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):



         4)       Proposed maximum aggregate value of transaction:



         5)       Total fee paid:



[  ]     Fee paid previously with preliminary materials.

[  ]     Check box if any part of the fee is offset as provided by Exchange
Act Rule  0-11(a)(2)  and identify the filing for which the offsetting fee was
paid  previously.  Identify the previous filing by  registration  statement
number, or the Form or Schedule and the date of its filing.

         1)       Amount Previously Paid:



         2)       Form, Schedule or Registration Statement No.:



         3)       Filing Party:



         4)       Date Filed:



     On September 7, 2004, Carl C. Icahn and his affiliates filed a Schedule 13D
with the  Securities  and Exchange  Commission,  which  schedule  contained  the
following statements in its Item 4 disclosure:

     "The Registrants  acquired the Shares because they believe the Shares to be
undervalued  in the  market  place.  Depending  on market  conditions  and other
factors, the Registrants may acquire additional Shares at any time and from time
to time, and may dispose of all or any portion of the Shares at any time or from
time to time.  The  Registrants'  present  intention  is to oppose  and  solicit
proxies against the Issuer's proposed merger with King Pharmaceuticals, Inc. The
Registrants have made plans to meet with Robert J. Coury, the Issuer's CEO, this
week.

     SECURITY  HOLDERS  ARE  ADVISED  TO READ  THE  PROXY  STATEMENT  AND  OTHER
DOCUMENTS  RELATED TO  SOLICITATION  OF PROXIES BY MR. ICAHN AND HIS  AFFILIATES
FROM THE STOCKHOLDERS OF MYLAN  LABORATORIES INC. FOR USE AT ITS SPECIAL MEETING
WHEN  AND  IF  THEY  BECOME  AVAILABLE   BECAUSE  THEY  WILL  CONTAIN  IMPORTANT
INFORMATION.  WHEN AND IF COMPLETED,  A DEFINITIVE PROXY STATEMENT AND A FORM OF
PROXY WILL BE MAILED TO  STOCKHOLDERS  OF MYLAN  LABORATORIES  INC.  AND WILL BE
AVAILABLE AT NO CHARGE AT THE  SECURITIES AND EXCHANGE  COMMISSION'S  WEBSITE AT
HTTP://WWW.SEC.GOV. "


     SECURITY  HOLDERS  ARE  ADVISED  TO READ  THE  PROXY  STATEMENT  AND  OTHER
DOCUMENTS  RELATED TO  SOLICITATION  OF PROXIES BY MR. ICAHN AND HIS  AFFILIATES
FROM THE STOCKHOLDERS OF MYLAN  LABORATORIES INC. FOR USE AT ITS SPECIAL MEETING
WHEN  AND  IF  THEY  BECOME  AVAILABLE   BECAUSE  THEY  WILL  CONTAIN  IMPORTANT
INFORMATION.  WHEN AND IF COMPLETED,  A DEFINITIVE PROXY STATEMENT AND A FORM OF
PROXY WILL BE MAILED TO  STOCKHOLDERS  OF MYLAN  LABORATORIES  INC.  AND WILL BE
AVAILABLE AT NO CHARGE AT THE  SECURITIES AND EXCHANGE  COMMISSION'S  WEBSITE AT
HTTP://WWW.SEC.GOV.  INFORMATION  RELATING TO THE  POTENTIAL  PARTICIPANTS  IN A
POTENTIAL PROXY SOLICITATION IS CONTAINED IN THE SCHEDULE 13D FILED BY MR. ICAHN
AND HIS AFFILIATES  WITH THE SECURITIES AND EXCHANGE  COMMISSION ON SEPTEMBER 7,
2004 WITH  RESPECT TO MYLAN  LABORATORIES  INC.  THAT  SCHEDULE 13D IS CURRENTLY
AVAILABLE AT NO CHARGE ON THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE.